Web5 de out. de 2024 · The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead that is placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2024. ONWARD is headquartered at the High Tech Campus in … Web21 de jun. de 2024 · 21st June 2024. 3662. ONWARD has announced the that it has received breakthrough device designation status from the US Food and Drug Administration (FDA) for their ARC-IM platform for blood pressure and trunk control in people with spinal cord injury. This is the third such breakthrough device designation for ONWARD, …
ONWARD Announces First Patient Enrolled in the Up-LIFT Pivotal …
Web27 de set. de 2024 · ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal-cord stimulation to restore movement... Web8 de dez. de 2024 · ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and ... sign in windows 10 using microsoft account
ONWARD Receives FDA Breakthrough Device Designation for ARC-IM …
WebHá 2 dias · Die ARC-Therapie von ONWARD, die mittels implantierbarer (ARC-IM) oder externer (ARC-EX) Systeme durchgeführt werden kann, dient der gezielten, … Web10 de mai. de 2024 · Onward Medical, a Dutch medical technology company that focuses on creating therapies for people with spinal cord injury (SCI), has enrolled the first patient in its HemON Study.. The move also marks the first-in-human use of its ARC IM implantable pulse generator (IPG). The device is programmed to stimulate the spinal cord and help … Web8 de jun. de 2024 · ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARC IM and ARC EX. The company’s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2024 with 65 subjects worldwide. The company completed first-in-human use of its ARC IM neurostimulator in May 2024. thera battery